Aktis Oncology, Inc. (AKTS)
Nasdaq · Pharmaceutical Preparations · Inc. DE
What they're doing
Not enough recent activity to summarise.
Signals, last 12 months
- Material 8-K filingFiled 8-K disclosing director or officer change
- Insider purchaseEcoR1 Capital, LLC; NODELMAN OLEG (director) bought $37.4M of stock
- Insider purchaseNODELMAN OLEG (director) bought $37.4M of stock
- Insider buying cluster6 insiders bought $114.3M within 14 days
- Insider purchaseGADICKE ANSBERT (ten_percent_owner) bought $20.0M of stock
- Insider purchaseGADICKE ANSBERT; MPM ASSET MANAGEMENT LLC; Oncology Impact Private Investment Fund 2, L.P. (ten_percent_owner) bought $20.0M of stock
- Insider purchaseMPM ONCOLOGY INNOVATIONS FUND LP (ten_percent_owner) bought $20.0M of stock
- Insider purchaseKim Helen Susan (director) bought $14.6M of stock
- Insider purchaseVIDA VENTURES II-A, LLC (ten_percent_owner) bought $14.6M of stock
- Insider purchaseFoley Todd (director) bought $4.2M of stock
- Insider purchaseFoley Todd (director) bought $4.2M of stock
- Insider purchaseNODELMAN OLEG (director) bought $2.6M of stock
- Insider purchaseVIDA VENTURES II-A, LLC (ten_percent_owner) bought $406k of stock
- Insider purchaseKim Helen Susan (director) bought $406k of stock
Insider transactions
| Date | Insider | Role | Code | Shares | Price | Value |
|---|---|---|---|---|---|---|
| 2026-09-23 | Czibere Akos | officer | S | 7,401 | 21.03 | $155,648 |
| 2026-09-23 | Czibere Akos | officer | S | 5,099 | 20.19 | $102,973 |
| 2026-09-23 | Czibere Akos | officer | M | 12,500 | 4.95 | $61,875 |
| 2026-07-20 | Herrmann Ken | director | M | 3,506 | 0.08 | $280 |
| 2026-07-20 | Herrmann Ken | director | M | 1,350 | 1.91 | $2,579 |
| 2026-07-20 | Herrmann Ken | director | S | 3,506 | 24.56 | $86,115 |
| 2026-07-20 | Herrmann Ken | director | S | 1,350 | 24.56 | $33,159 |
| 2026-07-17 | Herrmann Ken | director | M | 3,065 | 0.08 | $245 |
| 2026-07-17 | Herrmann Ken | director | S | 3,065 | 25.21 | $77,259 |
| 2026-07-08 | Ron-Bigger Shulamit | officer | M | 50,000 | 3.66 | $183,000 |
| 2026-07-08 | Ron-Bigger Shulamit | officer | S | 15,800 | 27.13 | $428,681 |
| 2026-07-08 | Ron-Bigger Shulamit | officer | S | 30,000 | 27.94 | $838,137 |
| 2026-07-08 | Ron-Bigger Shulamit | officer | S | 4,200 | 28.75 | $120,740 |
| 2026-07-08 | Czibere Akos | officer | M | 50,000 | 4.95 | $247,500 |
| 2026-07-08 | Czibere Akos | officer | S | 14,800 | 27.13 | $401,484 |
| 2026-07-08 | Czibere Akos | officer | S | 30,829 | 27.95 | $861,735 |
| 2026-07-08 | Czibere Akos | officer | S | 4,371 | 28.71 | $125,482 |
| 2026-01-12 | Foley Todd | director | C | 2,688,270 | — | — |
| 2026-01-12 | Foley Todd | director | P | 232,870 | 18 | $4,191,660 |
| 2026-01-12 | Foley Todd | director | C | 597,391 | — | — |
| 2026-01-12 | Foley Todd | director | C | 716,872 | — | — |
| 2026-01-12 | MPM ONCOLOGY INNOVATIONS FUND LP | ten percent owner | C | 1,577,119 | — | — |
| 2026-01-12 | MPM ONCOLOGY INNOVATIONS FUND LP | ten percent owner | C | 5,914,197 | — | — |
| 2026-01-12 | MPM ONCOLOGY INNOVATIONS FUND LP | ten percent owner | C | 1,314,262 | — | — |
| 2026-01-12 | MPM ONCOLOGY INNOVATIONS FUND LP | ten percent owner | P | 1,112,777 | 18 | $20,029,986 |
| 2026-01-12 | GADICKE ANSBERT | ten percent owner | C | 1,314,262 | — | — |
| 2026-01-12 | GADICKE ANSBERT | ten percent owner | P | 1,112,777 | 18 | $20,029,986 |
| 2026-01-12 | GADICKE ANSBERT | ten percent owner | C | 1,577,119 | — | — |
| 2026-01-12 | GADICKE ANSBERT | ten percent owner | C | 5,914,197 | — | — |
| 2026-01-12 | NODELMAN OLEG | director | P | 2,077,779 | 18 | $37,400,022 |
| 2026-01-12 | NODELMAN OLEG | director | C | 128,506 | — | — |
| 2026-01-12 | NODELMAN OLEG | director | C | 202,862 | — | — |
| 2026-01-12 | NODELMAN OLEG | director | C | 2,270,879 | — | — |
| 2026-01-12 | NODELMAN OLEG | director | P | 144,443 | 18 | $2,599,974 |
| 2026-01-12 | VIDA VENTURES II-A, LLC | ten percent owner | C | 4,859,370 | — | — |
| 2026-01-12 | VIDA VENTURES II-A, LLC | ten percent owner | P | 22,545 | 18 | $405,810 |
| 2026-01-12 | VIDA VENTURES II-A, LLC | ten percent owner | C | 134,842 | — | — |
| 2026-01-12 | VIDA VENTURES II-A, LLC | ten percent owner | P | 812,455 | 18 | $14,624,190 |
| 2026-01-12 | Segal Lloyd Mitchell | director | C | 19,631 | — | — |
| 2026-01-12 | Kim Helen Susan | director | C | 4,859,370 | — | — |
| 2026-01-12 | Kim Helen Susan | director | P | 22,545 | 18 | $405,810 |
| 2026-01-12 | Kim Helen Susan | director | C | 134,842 | — | — |
| 2026-01-12 | Kim Helen Susan | director | P | 812,455 | 18 | $14,624,190 |
| 2026-01-12 | Foley Todd | director | C | 597,391 | — | — |
| 2026-01-12 | Foley Todd | director | C | 2,688,270 | — | — |
| 2026-01-12 | Foley Todd | director | C | 716,872 | — | — |
| 2026-01-12 | Foley Todd | director | P | 232,870 | 18 | $4,191,660 |
| 2026-01-12 | MPM BIOVENTURES 2018, L.P.; EVNIN LUKE; MPM BIOVENTURES 2018 (B), L.P.; MPM BioVentures 2018 LLC; MPM BioVentures 2018 GP LLC; MPM ASSET MANAGEMENT INVESTORS BV2018 LLC; MPM ONCOLOGY INNOVATIONS FUND LP; MPM Oncology Innovations Fund GP LLC | ten percent owner | C | 1,314,262 | — | — |
| 2026-01-12 | MPM BIOVENTURES 2018, L.P.; EVNIN LUKE; MPM BIOVENTURES 2018 (B), L.P.; MPM BioVentures 2018 LLC; MPM BioVentures 2018 GP LLC; MPM ASSET MANAGEMENT INVESTORS BV2018 LLC; MPM ONCOLOGY INNOVATIONS FUND LP; MPM Oncology Innovations Fund GP LLC | ten percent owner | C | 5,914,197 | — | — |
| 2026-01-12 | MPM BIOVENTURES 2018, L.P.; EVNIN LUKE; MPM BIOVENTURES 2018 (B), L.P.; MPM BioVentures 2018 LLC; MPM BioVentures 2018 GP LLC; MPM ASSET MANAGEMENT INVESTORS BV2018 LLC; MPM ONCOLOGY INNOVATIONS FUND LP; MPM Oncology Innovations Fund GP LLC | ten percent owner | C | 1,577,119 | — | — |
Federal contracts
No federal contract actions on record for this recipient mapping.
Lobbying
No federal lobbying filings on record for this client mapping.
Public attention
No Wikipedia pageview data linked to this company.